Beacon Equity Issues Trading Outlook for Advanced Life Sciences Inc.

• Press Release
• Source: Beacon Equity
• On 6:50 am EDT, Tuesday July 28, 2009

DALLAS, July 28, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring pharmaceutical company Advanced Life Sciences Inc. (OTCBB:ADLS - News). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

Related Quotes

Symbol	Price	Change
ADLS.OB	0.22	0.00

{"s" : "adls.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The investment report on Advanced Life Sciences Inc. (OTCBB:ADLS - News) should be of particular interest to other pharmaceutical companies: GlaxoSmithKline plc. (NYSE:GSK - News), Johnson & Johnson (NYSE:JNJ - News), Pfizer Inc. (NYSE:PFE - News) and Genzyme Corp. (Nasdaq:GENZ - News).

The full report is available at: http://www.beaconequity.com/i/ADLS

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Advanced Life Sciences Inc. (ADLS) is an emerging pharmaceutical company focused on the development and commercialization of novel drugs for the treatment of infectious disease, oncology and respiratory disorders. Its lead drug candidate Cethromycin, which is developed for the treatment of acquired pneumonia, cleared phase III clinical trials. In addition, the Company maintains licensing agreements with Abbott Laboratories for worldwide commercialization and further development of Cethromycin. The Company also has a portfolio of drug therapies candidates under preclinical trials, including ALS-357 to treat melanoma, and ALS-886 to treat acute respiratory distress.

In the report, the analyst notes:

"Following rapid growth rates from 2004 to 2008, drug sales of respiratory related conditions is expected to reach $23 billion by 2018, according to The Datamonitor Group, while the most recent statistics for the global market potential of the Company's ALS-357 anti-cancer drug therapy could reach approximately $53 billion for 2009.

"If approved by the U.S. Food and Drug Administration (FDA), the market for ADLS' drug candidate Cethromycin could reach more than $1 billion at its market saturation. Cethromycin has cleared phase III clinical trials, with the prospects of reaching commercialization reaching approximately 90% following final approval from the FDA."

To read the entire report visit: http://www.beaconequity.com/i/ADLS

BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com